- Design
- Reconstructed individual patient data meta-analysis of 3 phase 3 RCTs
- Population
- 2,590 patients with BCG-naive high-risk NMIBC
- Primary outcome
- Event-free survival with checkpoint inhibitor plus BCG induction and maintenance
- Effect
- HR 0.77 (0.64–0.93); grade ≥3 AEs 24.5% vs 6.1%
A meta-analysis reconstructed individual patient data from the published survival curves of three phase 3 trials (CREST, POTOMAC and ALBAN; 2,590 patients) testing a checkpoint inhibitor added to BCG in BCG-naive high-risk non-muscle-invasive bladder cancer. It was published in August 2026.
With BCG induction and maintenance, adding a checkpoint inhibitor improved event-free survival (HR 0.77, 95% CI 0.64 to 0.93), confirmed in an aggregate analysis. With induction-only BCG there was no benefit (HR 1.03). Overall survival data were immature (HR 0.90, not significant). Grade 3 or higher adverse events occurred in 24.5% with the combination and 6.1% with BCG alone.
The pattern suggests the combination works only when BCG is given fully, and that the gain in event-free survival comes at a substantial cost in toxicity, without proof yet of longer life.
Where BCG supply is limited, as during recurrent global shortages, the requirement for full maintenance is a practical constraint on any combination strategy.
- Prioritise complete BCG induction and maintenance in high-risk NMIBC.
- Do not expect a checkpoint inhibitor to compensate for incomplete BCG.
- Discuss the fourfold rise in severe adverse events before combination therapy.
- Await overall survival data before treating combination therapy as standard.
Why it matters
It shows the combination's benefit hinges on BCG delivery, which shortages often interrupt.
Don't overread it
Event-free survival improved, but overall survival has not yet been shown to differ.
The statistics, in plain English
A hazard ratio of 0.77 means events occurred about 23% less often with the combination. Reconstructing patient data from published curves is an approximation, though it matched the aggregate result here.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free